Two pharmaceutical companies awarded a share of South Africa’s latest Aids drug tender are in business rescue and have struggled to consistently supply the state. Avacare Health subsidiaries Barrs and Innovata each won portions of the core contract to supply TLD. Most HIV patients use this three-in-one antiretroviral pill. Both entities entered business rescue in December. Therefore, this raised concerns…
Tag: HIV
-
HIV Treatment Retention: South Africa’s Plan for 1.1m Patients
South Africa’s globally acclaimed response to the HIV epidemic has hit a critical “stubborn and painful” hurdle. While the nation has made massive strides in diagnosis and viral suppression, Deputy President Paul Mashatile has warned that HIV treatment retention is now the primary threat to the country’s healthcare sustainability. The Department of Health reports that 1.1 million patients stopped attending…
-
Digital Primary Healthcare in Africa: Building Resilience
The recent decision by major donor countries to reduce global health funding has sent shockwaves through sub-Saharan Africa. The consequences of stop-work orders issued in January 2025 have already impacted HIV programmes and other critical health responses. However, this crisis presents a vital opportunity for African nations to take greater ownership of their health systems. It can be done by…
-
TB Deaths Decline to 54,000, But Critical Treatment Gaps Remain
South Africa recorded approximately 54,000 deaths from tuberculosis (TB) in 2024, according to the latest World TB Report from the World Health Organisation (WHO). The figures confirm a slow but steady downward trend in TB deaths in recent years. This marks a significant improvement from two decades ago. During that time, the epidemic, fueled by the peak of the HIV…
-
TB Epidemic Challenges and Local Manufacturing Needs
The South African National AIDS Council (SANAC) has issued an urgent call for the establishment of secure medical supply chains and the enhancement of local manufacturing capacity. They warn that medicine stockouts and diagnostic delays are costing lives and undermining efforts to end the tuberculosis (TB) epidemic. This critical demand was made during the official relaunch of the South African…
-
African Philanthropists Must Drive Change in Public Health
The head of the Global Fund to Fight AIDS, Tuberculosis, and Malaria has issued a powerful call to action for African philanthropists. He urges them to direct their resources towards health initiatives. These efforts could save millions of lives and transform the continent’s future. Speaking from the sidelines of the World Health Summit in Berlin, Executive Director Peter Sands made…
-
SA’s Life Expectancy Declines as NCDs Surge
In a concerning reversal of global progress, SA’s life expectancy in 2023 was lower than it was over three decades ago, according to a landmark study. The relentless rise of non-communicable diseases (NCDs) such as diabetes and stroke is now actively undermining the country’s historic successes in combating the HIV/AIDS epidemic. This creates a perilous “double burden” for its healthcare…
-
Lenacapavir Access Under Scrutiny by Health Advocates
A global coalition of health advocates is intensifying its campaign against pharmaceutical giant Gilead Sciences. They demand equitable access to its revolutionary long-acting injectable HIV prevention drug, lenacapavir. Activists are calling for a universal generic price of $40 per person per year for all low and middle-income countries. They warn that Gilead’s current policies entrench life-threatening inequities in the global…
-
UNAIDS Closure Causes Outrage Among Health Advocates
South African health advocates have issued a stark warning. They believe the planned closure of the Joint UN Programme on HIV/Aids (UNAIDS) will have a devastating effect on millions of lives. This also risks derailing decades of progress in the global fight against the epidemic. According to a United Nations document released this week, the United Nations will “sunset” the…
-
Generic HIV Prevention Drug to Cost Just $40 Annually from 2027
In a monumental step forward for global public health, Indian pharmaceutical companies Dr Reddy’s Laboratories and Hetero Labs have announced they will produce and sell generic versions of a revolutionary HIV prevention drug. It will be available for around $40 per year. Availability is expected from 2027. The drug, lenacapavir, is a long-acting injectable developed by Gilead Sciences. It has…